Briejer M R, Schuurkes J A, Sarna S K
Department of Gastrointestinal Pharmacology, Janssen Research Foundation, Beerse, Belgium.
Trends Pharmacol Sci. 1999 Jan;20(1):1-3. doi: 10.1016/s0165-6147(98)01278-4.
The precise abnormalities of colonic motility patterns in idiopathic constipation, and the alterations at the cellular, neural, myogenic and biochemical levels that underlie these patterns, are not yet understood. One promising approach in the treatment of constipation seems to be to design drugs that can stimulate GMCs to produce mass movements and consequently defaecation. This could possibly be achieved with the selective 5-HT4 receptor agonists prucalopride and SDZ HTF-919, which are currently in advanced clinical trials. Other mechanisms that provide a means to induce GMCs, such as NK1 receptor agonism, deserve further exploration.
特发性便秘中结肠动力模式的确切异常情况，以及构成这些模式基础的细胞、神经、肌源性和生化水平的改变，目前尚不清楚。治疗便秘的一种有前景的方法似乎是设计能刺激集团蠕动收缩（GMCs）以产生推进性蠕动并进而促进排便的药物。这可能通过选择性5-羟色胺4（5-HT4）受体激动剂普芦卡必利和SDZ HTF-919来实现，这两种药物目前正处于高级临床试验阶段。其他诱导集团蠕动收缩的机制，如NK1受体激动作用，值得进一步探索。
